Levetiracetam Injection, Solution, Concentrate
Product Images NDC 36000-265

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 36000-265). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Baxter Healthcare Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

500-mg-5ml-carton-of-10 (500 mg 5ml Carton Of 10)

500-mg-5ml-carton-of-10 (500 mg 5ml Carton Of 10)
Packaging label for Levetiracetam Injection, USP 500 mg/5 mL (100 mg/mL) concentrate for intravenous use by Baxter Healthcare Corporation. The label includes dosage instructions, storage conditions, and states the product is for intravenous use only, requiring dilution prior to administration. It contains 10 x 5 mL single-dose vials, with manufacturer Baxter Pharmaceuticals India Private Ltd, and includes the NDC 36000-265-10.*
FDA Label Image

500-mg-5ml-carton-of-5 (500 mg 5ml Carton Of 5)

500-mg-5ml-carton-of-5 (500 mg 5ml Carton Of 5)
Packaging label for Levetiracetam Injection, USP 500 mg/5 mL (100 mg/mL) concentrate injection for intravenous use, manufactured by Baxter Pharmaceuticals India Private Ltd and labeled by Baxter Healthcare Corporation. The carton indicates 5 x 5 mL single-dose vials and includes instructions stating it must be diluted prior to administration and unused portion discarded. The label includes NDC 36000-265-05 and storage recommendations.*
FDA Label Image

500-mg-5ml-label.jpg (500 mg 5ml Label)

500-mg-5ml-label.jpg (500 mg 5ml Label)
Label for Levetiracetam Injection, USP 500 mg/5 mL (100 mg/mL) intravenous injection solution concentrate, single-dose vial. The label states it is for intravenous use only, must be diluted before administration, and unused portions discarded. Manufactured for Baxter Healthcare Corporation, Deerfield, IL, USA, and made in India.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A vertical bar chart comparing the percentage of patients among three groups: Placebo (7.4%), KEPPRA 1000 mg/day (37.1%), and KEPPRA 3000 mg/day (39.6%). The y-axis represents percentage of patients from 0% to 45%, and each bar includes the sample size (N) for each group.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A bar graph showing the percentage of patients responding to placebo and levetiracetam at dosages of 1000 mg/day and 2000 mg/day. The y-axis indicates percentage from 0% to 45%, and bars show approximately 6.3% for placebo, 20.8% for levetiracetam 1000 mg/day, and 35.2% for levetiracetam 2000 mg/day. The graph compares patient response rates across three groups.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A bar graph comparing the percentage of patients for placebo and Levetiracetam 3000 mg/day groups. The x-axis displays the treatments: Placebo (N=104) and Levetiracetam 3000 mg/day (N=180). The y-axis represents the percentage of patients, ranging from 0% to 45%. The placebo group shows 14.4%, while the Levetiracetam group shows 39.4%, with an asterisk on the Levetiracetam bar.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A bar graph comparing the percentage of patients in two groups: Placebo (N=97) and Levetiracetam (N=101). The y-axis represents the percentage of patients, ranging from 0% to 45%. The Placebo group shows 19.6% of patients, while the Levetiracetam group shows 44.6%, with an asterisk indicating statistical significance or emphasis on this value.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
A bar chart comparing the percentage of patients in two groups: Placebo (N=51) and Levetiracetam (N=58). The vertical axis represents the percentage of patients from 0% to 45%. The Placebo group shows 19.6%, while the Levetiracetam group shows 43.1%, with a notable asterisk indicating statistical significance or emphasis on the Levetiracetam bar.*
FDA Label Image

Figure-6 (Figure 6)

Figure-6 (Figure 6)
A bar chart comparing the percentage of patients between placebo and levetiracetam groups. The y-axis represents the percentage of patients from 0% to 100%. The placebo group (N=84) shows 45.2%, while the levetiracetam group (N=79) shows 72.2%, marked with an asterisk indicating statistical significance.*
FDA Label Image

Structural-formula (Structural Formula)

Structural-formula (Structural Formula)
Chemical structure diagram of levetiracetam, showing a five-membered ring with a nitrogen atom, a carbonyl group, an ethyl side chain, a hydrogen atom, and a carboxamide group attached to a central carbon atom.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.